ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2022

Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.

Guoqiao Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.